MedTrace Logo

Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment

NCT02812654 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2016-06-24

No results posted yet for this study

Summary

Prospective phase II study. Patients will be submitted to neoadjuvant chemotherapy (cT) and hypo fractionated radiotherapy (hRT) following by surgery. The remain viable cells will be analyzed and the patients whithin less than 30% will receive more 3 cycles of cT. All patients have deep high grade soft tissue sarcoma of extremity.

Conditions

  • Sarcoma, Soft Tissue

Interventions

DRUG

Doxorubicin

Doxorubicin 75mg/m2 (cycle 1,2 and 3)

DRUG

Ifosfamide

Ifosfamide 9 g/m2 (cycle 1 and 3)

RADIATION

radiotherapy

radiotherapy: 25 Gy / 5 x 500 cGy/day

Sponsors & Collaborators

  • AC Camargo Cancer Center

    lead OTHER

Principal Investigators

  • Ademar Lopes, Phd · A.C.Camargo Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2018-12-31
Completion
2019-03-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02812654 on ClinicalTrials.gov